Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome

Recruiting Observational Study
Uveal Melanoma Cutaneous Melanoma BAP1 Gene Mutation Renal Cell Carcinoma Mesothelioma Hepatocellular Carcinoma Cholangiocarcinoma Meningioma Atypical
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Study type
Observational
Participants needed
500 (estimated)
Sponsor
Mohamed Abdel-Rahman · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1. Our study will ultimately facilitate the development of novel screening, prevention and treatment strategies for these individuals with the syndrome. Because the vast majority of UM develop in pre-existi…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Patients who meet any of the following criteria: 1. Personal history of one cancer reported in BAP1 cancer predisposition syndrome and family history of at least two 1st or 2nd degree relatives with cancer reported in hereditary BAP1 cancer predisposition syndrome such as UM, C…
Contacts

Mohamed H Abdel-Rahman, MD, PhD

614-292-1396

Mohamed.Abdel-Rahman@osumc.edu

CONTACT